References
- Campo G, Pavasini R, Malagù M, Mascetti S, Biscaglia S, Ceconi C, et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc Drugs Ther 2015; 29(2):147–157.
- The Global Initiative for Chronic Obstructive Lung Disease. Updated 2015. (http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html) (accessed January 2015)
- Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166(3):333–339.
- Pavasini R, d'Ascenzo F, Campo G, Biscaglia S, Ferri A, Contoli M, et al. Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. Int J Cardiol 2015; 191:187–193.
- Maclay JD, McAllister DA, Johnston S, Raftis J, McGuinnes C, Deans A, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011; 66(6):769–774.
- Campo G, Pavasini R, Pollina A, Tebaldi M, Ferrari R. On-treatment platelet reactivity in patients with chronic obstructive pulmonary disease undergoing percutaneous coronary intervention. Thorax 2014; 69(1):80–81.
- Wang RT, Li JY, Cao ZG, Li Y. Mean platelet volume is decreased during an acute exacerbation of chronic obstructive pulmonary disease. Respirology 2013; 18(8):1244–1248.
- Harrison MT, Short P, Williamson PA, Singanayagam A, Chalmers JD, Schembri S. Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease: a role for antiplatelet therapy? Thorax 2014; 69(8):609–615.
- Campo G, Pavasini R, Malagù M, Punzetti S, Napoli N, Guerzoni F, et al. Relationship between troponin elevation, cardiovascular history and cardiac adverse events in patients with acute exacerbation of COPD. COPD 2015; Aug 19: 1–8.
- Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999; 354(9193):1896–1900.
- Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283(15):2008–2012.
- Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2, The Cochrane Collaboration, (updated March 2011) 2009. Available from: http://handbook.cochrane.org/.
- Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339:b2700.
- DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trial 1986; 7(3):177–188.
- Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414):557–560.
- Ekström MP, Hermansson AB, Ström KE. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(7):715–720.
- Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342:d2549.
- Søyseth V, Brekke PH, Smith P, Omland T. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007; 29(2):279–283.
- Campo G, Guastaroba P, Marzocchi A, Santarelli A, Varani E, Vignali L et al. Impact of COPD on long-term outcome after ST-segment elevation myocardial infarction receiving primary percutaneous coronary intervention. Chest 2013; 144(3):750–757.
- McAllister DA, Maclay JD, Mills NL, Leitch A, Reid P, Carruthers R et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J 2012; 39(5):1097–1103.